A phase II study of radioimmunotherapy with intraventricular (131)I-3F8 for medulloblastoma

BACKGROUND: High-risk and recurrent medulloblastoma (MB) is associated with significant mortality. The murine monoclonal antibody 3F8 targets the cell-surface disialoganglioside GD2 on MB. We tested the efficacy, toxicity, and dosimetry of compartmental radioimmunotherapy (cRIT) with intraventricula...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Blood Cancer
Autors principals: Kramer, Kim, Pandit-Taskar, Neeta, Humm, John L., Zanzonico, Pat B., Haque, Sofia, Dunkel, Ira J., Wolden, Suzanne L., Donzelli, Maria, Goldman, Debra A., Lewis, Jason S., Lyashchenko, Serge K., Khakoo, Yasmin, Carrasquillo, Jorge A., Souweidane, Mark M., Greenfield, Jeffrey P., Lyden, David, De Braganca, Kevin D., Gilheeney, Stephen W., Larson, Steven M., Cheung, Nai-Kong V.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692907/
https://ncbi.nlm.nih.gov/pubmed/28940863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26754
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars